Browse News
Filter News
Found 1,516 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Point Of Care Diagnostics Market Size to Increase USD 80.75 Bn by 2033
4/17/2024
According to Nova One Advisor, the global point of care diagnostics market size was accounted for USD 44.25 billion in 2023 and it will increase to around USD 80.75 billion by 2033 with a CAGR of 6.2% from 2024 to 2033.
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/16/2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
-
The American Society of Health-System Pharmacists has released statistics showing the number of active and ongoing U.S. drug shortages has reached 323, the highest number since it began tracking the data.
-
Clinical Trials Market Size to Increase USD 153.59 Billion by 2033
4/9/2024
According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.
-
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
3/28/2024
Zura Bio Limited a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, reported full year 2023 financial results and recent business highlights.
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/27/2024
Precision BioSciences, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
-
Separate challenges exist for companies developing gene therapies for rare and common cardiovascular conditions, experts told BioSpace.
-
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
3/8/2024
Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update.
-
Companies inked 204 deals in the fourth quarter of 2023 with venture capital funding slipping to $6.3 billion from $7.8 billion in the third quarter last year, according to market data firm Pitchbook.
-
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
2/28/2024
HUTCHMED Limited, the innovative, commercial-stage biopharmaceutical company, reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments.
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
2/28/2024
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update.
-
Two surprise companies, Vertex Pharmaceuticals and Regeneron Pharmaceuticals, made GlobalData’s list with 41.4% and 21.8% market capitalization growth, respectively.
-
Novo Nordisk seems to believe it can do a better job managing troubled Catalent than the contract manufacturer. However, the Danish drugmaker has its work cut out for it.
-
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
2/13/2024
Precision BioSciences, Inc. today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations.
-
Biopharma’s latest earnings season was, in a word, predictable. Companies are consistently beating Wall Street earnings and revenue estimates as they set low expectations for investors.
-
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
2/7/2024
Moderna, Inc. announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering, broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine.".
-
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
2/6/2024
Eli Lilly and Company announced its financial results for the fourth quarter of 2023.
-
The biotech is taking a synergistic approach to obesity with two muscle-preserving antibodies set to enter a Phase II study in mid-2024 in combination with existing incretin-based treatments.
-
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
1/30/2024
HUTCHMED Limited announces that the marketing approval of ELUNATE® by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer.